These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 27624768)

  • 21. The role of infection models and PK/PD modelling for optimising care of critically ill patients with severe infections.
    Tängdén T; Ramos Martín V; Felton TW; Nielsen EI; Marchand S; Brüggemann RJ; Bulitta JB; Bassetti M; Theuretzbacher U; Tsuji BT; Wareham DW; Friberg LE; De Waele JJ; Tam VH; Roberts JA;
    Intensive Care Med; 2017 Jul; 43(7):1021-1032. PubMed ID: 28409203
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antimicrobial pharmacokinetic and pharmacodynamic issues in the critically ill with severe sepsis and septic shock.
    Varghese JM; Roberts JA; Lipman J
    Crit Care Clin; 2011 Jan; 27(1):19-34. PubMed ID: 21144984
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Are β-lactam concentrations adequate in severe sepsis and septic shock in children?
    Chosidow A; Benaboud S; Beranger A; Zheng Y; Moulin F; Dupic L; Renolleau S; Treluyer JM; Oualha M
    Therapie; 2020; 75(6):633-640. PubMed ID: 32593420
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bench-to-bedside review: Appropriate antibiotic therapy in severe sepsis and septic shock--does the dose matter?
    Pea F; Viale P
    Crit Care; 2009; 13(3):214. PubMed ID: 19519961
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics of meropenem in critically ill patients with severe infections.
    Binder L; Schwörer H; Hoppe S; Streit F; Neumann S; Beckmann A; Wachter R; Oellerich M; Walson PD
    Ther Drug Monit; 2013 Feb; 35(1):63-70. PubMed ID: 23318279
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Beta-Lactam Infusion in Severe Sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis.
    Abdul-Aziz MH; Sulaiman H; Mat-Nor MB; Rai V; Wong KK; Hasan MS; Abd Rahman AN; Jamal JA; Wallis SC; Lipman J; Staatz CE; Roberts JA
    Intensive Care Med; 2016 Oct; 42(10):1535-1545. PubMed ID: 26754759
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetic and Pharmacodynamic Efficacies of Continuous versus Intermittent Administration of Meropenem in Patients with Severe Sepsis and Septic Shock: A Prospective Randomized Pilot Study.
    Zhao HY; Gu J; Lyu J; Liu D; Wang YT; Liu F; Zhu FX; An YZ
    Chin Med J (Engl); 2017 May; 130(10):1139-1145. PubMed ID: 28485312
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapeutic drug monitoring of carbapenem antibiotics in critically ill patients: an overview of principles, recommended dosing regimens, and clinical outcomes.
    Joynt GM; Ling L; Wong WT; Lipman J
    Expert Rev Clin Pharmacol; 2023; 16(8):703-714. PubMed ID: 36942827
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetic and pharmacodynamic considerations when treating patients with sepsis and septic shock.
    De Paepe P; Belpaire FM; Buylaert WA
    Clin Pharmacokinet; 2002; 41(14):1135-51. PubMed ID: 12405864
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A personalised approach to antibiotic pharmacokinetics and pharmacodynamics in critically ill patients.
    Heffernan AJ; Mohd Sazlly Lim S; Lipman J; Roberts JA
    Anaesth Crit Care Pain Med; 2021 Dec; 40(6):100970. PubMed ID: 34728411
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Repeated Piperacillin-Tazobactam Plasma Concentration Measurements in Severely Obese Versus Nonobese Critically Ill Septic Patients and the Risk of Under- and Overdosing.
    Jung B; Mahul M; Breilh D; Legeron R; Signe J; Jean-Pierre H; Uhlemann AC; Molinari N; Jaber S
    Crit Care Med; 2017 May; 45(5):e470-e478. PubMed ID: 28240688
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Practical considerations for individualizing drug dosing in critically ill adults receiving renal replacement therapy.
    Kanji S; Roger C; Taccone FS; Muller L
    Pharmacotherapy; 2023 Nov; 43(11):1194-1205. PubMed ID: 37491976
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The influence of acute kidney injury on antimicrobial dosing in critically ill patients: are dose reductions always necessary?
    Blot S; Lipman J; Roberts DM; Roberts JA
    Diagn Microbiol Infect Dis; 2014 May; 79(1):77-84. PubMed ID: 24602849
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis.
    Roberts JA; Lipman J
    Clin Pharmacokinet; 2006; 45(8):755-73. PubMed ID: 16884316
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetic aspects of beta-lactam antibiotic therapy in intensive care unit patients: A one-center experience with TDM.
    Sadilová K; Halačová M; Černý D
    Ceska Slov Farm; 2020; 69(1):17-23. PubMed ID: 32460506
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Population pharmacokinetic modeling and optimal sampling strategy for Bayesian estimation of amikacin exposure in critically ill septic patients.
    Delattre IK; Musuamba FT; Nyberg J; Taccone FS; Laterre PF; Verbeeck RK; Jacobs F; Wallemacq PE
    Ther Drug Monit; 2010 Dec; 32(6):749-56. PubMed ID: 20962708
    [TBL] [Abstract][Full Text] [Related]  

  • 37. β-Lactam Therapeutic Drug Monitoring in Critically Ill Patients: Weighing the Challenges and Opportunities to Assess Clinical Value.
    Dilworth TJ; Schulz LT; Micek ST; Kollef MH; Rose WE
    Crit Care Explor; 2022 Jul; 4(7):e0726. PubMed ID: 35815181
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antibiotic dose optimization in critically ill patients.
    Cotta MO; Roberts JA; Lipman J
    Med Intensiva; 2015 Dec; 39(9):563-72. PubMed ID: 26415688
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics/Pharmacodynamics of β-Lactams and Therapeutic Drug Monitoring: From Theory to Practical Issues in the Intensive Care Unit.
    Williams P; Cotta MO; Roberts JA
    Semin Respir Crit Care Med; 2019 Aug; 40(4):476-487. PubMed ID: 31585474
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic Drug Monitoring of Beta-Lactams and Other Antibiotics in the Intensive Care Unit: Which Agents, Which Patients and Which Infections?
    Muller AE; Huttner B; Huttner A
    Drugs; 2018 Mar; 78(4):439-451. PubMed ID: 29476349
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.